Globe Newswire

• CUPID is a Phase I safety and dosimetry study of TLX592, Telix’s investigational antibody-based targeted alpha therapy for prostate cancer.
• Establishes proof-of-concept for Telix’s proprietary RADmAb® engineered antibody platform, currently under pre-clinical evaluation for multiple cancer targets.
• Initial results demonstrate rapid elimination from blood circulation compared to standard antibodies and hepatic (liver) clearance – both highly desirable... (continue reading...)

Reported figures all in U.S. Dollars

Announces Continued, Consistent Revenue Growth with Increasing Fixed Cost Leverage

Boston, MA, May 20, 2024 (GLOBE NEWSWIRE) -- MiniLuxe Holding Corp. (TSXV: MNLX) today announced its financial results for the 13 weeks ended March 31, 2024 (“Q1 2024”). The fiscal year of MiniLuxe is a 52-week reporting cycle ending on the Sunday closest to December 31, which periodically necessitates a fiscal year of 53 weeks; fiscal years... (continue reading...)

BELO HORIZONTE, Brazil, May 20, 2024 (GLOBE NEWSWIRE) -- Inter&Co (NASDAQ: INTR), the financial super app serving over 32 million customers across the Americas, announced today that S&P Global Ratings (S&P) has upgraded Banco Inter outlook to "Stable" and reaffirmed its "brAA+" local rating. In the report S&P stated that: "The stable outlook reflects our view that Inter&Co will continue to improve its profitability, providing greater stability to the business." 

... (continue reading...)

BELO HORIZONTE, Brazil, May 20, 2024 (GLOBE NEWSWIRE) -- Inter&Co (NASDAQ: INTR), the financial super app serving over 32 million customers across the Americas, announced today that S&P Global Ratings (S&P) has upgraded Banco Inter outlook to "Stable" and reaffirmed its "brAA+" local rating. In the report S&P stated that: "The stable outlook reflects our view that Inter&Co will continue to improve its profitability, providing greater stability to the business." 

... (continue reading...)

NEW YORK, May 20, 2024 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of GoodRx Holdings, Inc. (NASDAQ: GDRX) between September 23, 2020 and November 8, 2022, both dates inclusive (the “Class Period”), of the important June 21, 2024 lead plaintiff deadline.

SO WHAT: If you purchased GoodRx common stock during the Class Period you may be entitled to compensation without payment of any out of pocket... (continue reading...)